Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Gharaibeh, Mahdi
McBride, Ali
Bootman, J. Lyle
Cranmer, Lee D.
Abraham, Ivo
机构：
[1] Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] Univ Arizona, Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.6605
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6605
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Optimized economic evaluation for the United States (US) of nab-paclitaxel plus gemcitabine (NAB-P plus GEM) FOLFIRINOX (FFX), and gemcitabine (GEM) as first-line treatment for metastatic pancreatic cancer (mPDA)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [3] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
    Goldstein, David
    Von Hoff, Daniel D.
    Chiorean, E. Gabriela
    Reni, Michele
    Tabernero, Josep
    Ramanathan, Ramesh K.
    Aly, Abdalla
    Botteman, Marc
    Wilkersen, Julia
    Margunato-Debay, Sandra
    Lu, Brian
    Louis, Chrystal Ursula
    Renschler, Markus Frederic
    McGovern, Desmond Micahel Thomas
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [5] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Phase I study of nivolumab (Nivo) plus nab-paclitaxel (nab-P) plus gemcitabine (Gem) in advanced pancreatic cancer (APC).
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward Jae-Hoon
    George, Ben
    Kalyan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David Michael
    Gutierrez, Martin
    Parikh, Aparna Raj
    Jain, Rishi
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal Ursula
    Ong, Teng Jin
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
  • [8] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (17) : 3718 - 3729
  • [9] Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 345 - 352
  • [10] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345